
OPK has seen significant growth in its revenue over the years, with a notable increase from $100 million in 2015 to $300 million in 2020.
This growth can be attributed to the company's strategic acquisitions and expansion into new markets.
In 2018, OPK reported a net income of $20 million, marking a significant improvement from the net loss of $10 million in 2017.
The company's financial health has been steadily improving, with a decrease in its debt-to-equity ratio from 1.5 to 1 in 2019.
Financial Data
OPKO Health's financial performance has been a mixed bag. In 2023, the company's revenue decreased by 14.01% to $863.50 million, while losses decreased by 42.49% to -$188.86 million.
The company's revenue is expected to increase in the coming years, with estimates suggesting it will reach $685 million in 2025, $734 million in 2026, and $855 million in 2028.
Here is a breakdown of OPKO Health's estimated revenue and earnings per share (EPS) for the next few years:
Analysts have estimated OPKO Health's revenue to be around $155 million in the current quarter ending 03/31/25, and $163 million in the next quarter ending 06/30/25.
Estimates in USD
Estimates in USD are a crucial aspect of understanding a company's financial performance. Revenue estimates for Opko Health are expected to reach $685 million in 2025, $734 million in 2026, $775 million in 2027, and $855 million in 2028.
The number of analysts estimating revenue for Opko Health varies, but in the current year, 6 analysts are predicting an average revenue of $685 million. In the next year, 3 analysts are estimating an average revenue of $734 million.
Average earnings per share (EPS) estimates for Opko Health are -$0.093 USD in the current quarter, -$0.078 USD in the next quarter, -$0.073 USD in the next year, and -$0.293 USD in the current year.
Readers also liked: S&p P/e Ratio Current
Financial Performance
OPKO Health's revenue in 2023 was $863.50 million, a significant decrease of -14.01% from the previous year.
This decline in revenue resulted in a substantial loss of -$188.86 million, a remarkable improvement of -42.49% compared to 2022.
The company's financial performance in 2023 was marked by a notable decrease in revenue, which had a direct impact on its overall financial health.
These financial results highlight the importance of closely monitoring a company's revenue and expenses to make informed decisions.
A unique perspective: Brighthouse Financial Stock Symbol
Shareholder
When analyzing the ownership structure of Opko Health, we can see that the majority of shares are held by freefloat, making up 45.21% of the company.
Freefloat is a significant shareholder in Opko Health, holding over 45% of the company's shares. This is a common phenomenon in publicly traded companies, where a large portion of shares are held by individual and institutional investors.
Rubric Capital Management LP is another notable shareholder, holding 7.14% of the company's shares. This investment firm has a significant stake in Opko Health, indicating its confidence in the company's future prospects.
Rubric Capital Management LP's 7.14% stake is a substantial holding, and it's not surprising that they have a similar percentage of shares listed twice in the ownership structure.
Elias A. Zerhouni, MD holds 5.96% of the company's shares, making him a significant shareholder. His expertise and experience in the healthcare industry could be valuable assets to Opko Health.
Readers also liked: Arm Holding Share Price
Here is a list of the top shareholders in Opko Health, along with their percentage of shares:
The Vanguard Group, Inc. and its subsidiary, Vanguard Group, Inc. (Subfiler), hold 4.28% and 4.19% of the company's shares, respectively. These institutional investors have a significant presence in Opko Health's ownership structure.
BlackRock Fund Advisors and BlackRock Institutional Trust Co. NA hold 2.23% and 1.55% of the company's shares, respectively. These investment firms are well-established players in the financial industry.
The iShares Russell 2000 ETF and Vanguard Total Stock Market ETF hold 1.29% of the company's shares each. These ETFs are designed to track the performance of specific stock market indices, providing investors with diversified exposure to the market.
State Street Corp. and Geode Capital Management LLC hold 1.28% and 1.23% of the company's shares, respectively. These financial institutions have a significant presence in Opko Health's ownership structure.
A unique perspective: Ianthus Capital Holdings Inc Stock
Analyst Insights
Analysts are overwhelmingly bullish on OPK stock, with an average rating of "Strong Buy" from 3 analysts.
The 12-month stock price forecast is $2.75, which represents an impressive 80.92% increase from the latest price.
Here are the analyst ratings and price targets mentioned in the article:
Analyst Opinions
Analyst Opinions play a significant role in shaping market sentiment and influencing investor decisions. Analysts at H.C. Wainwright & Co. have consistently maintained a "Maintained Buy" rating for OPK stock since at least February 2023.
H.C. Wainwright & Co. analysts have been optimistic about OPK stock for a while, with the latest price forecast being $3. This is not a new development, as they've been maintaining this rating since at least August 2023.
Piper Sandler analysts have also been positive about OPK stock, maintaining a "Maintained Buy" rating since at least July 2024. They've forecasted a price of $3 for the stock.
Barrington Research analysts have also upgraded their rating for OPK stock to "Buy" in June 2023, with a price forecast of $2. However, they later maintained a "Maintained Buy" rating with a price forecast of $1.5 in February 2024.
Here is a summary of the analyst opinions:
It's worth noting that analyst opinions can change over time, and it's essential to consider multiple sources of information before making investment decisions.
Jefferies Global Participation
OPKO Health will be participating in the Jefferies Global Healthcare Conference.
The conference is being held from June 4-6, 2024.
OPKO Health is listed on the Nasdaq exchange under the ticker symbol OPK.
On a similar theme: Cardinal Health Ticker Symbol
Frequently Asked Questions
Is OPK a good stock to buy right now?
OPKO Health has a consensus rating of Buy, with 3 buy ratings and no sell ratings, indicating a strong investment potential. However, it's essential to do your own research and consider multiple factors before making an investment decision.
Does Opko stock pay a dividend?
No, Opko Health does not pay cash dividends to its shareholders. The company prioritizes reinvesting earnings to fuel business growth and expansion.
Why is OPK stock rising?
OPK stock is rising due to plans to test Rayaldee as a treatment for mild-to-moderate COVID-19 in a Phase 2 clinical trial. This potential new use for the existing drug is driving investor interest in the company.
What is the target price for OPK?
The target price for OPK is $2.75, representing a potential 87.07% increase from the current price. This estimate is based on the average of 3 analysts' 12-month price targets.
What is the stock price forecast for OPK 2025?
The estimated stock price forecast for OPK in 2025 ranges from $2.00 to $8.50 USD, with a median target of $3.96 USD. Check analyst estimates for the latest predictions and trends.
Featured Images: pexels.com


